ALKBH1 and gastric adenocarcinoma: While targeting the ALKBH1 signaling axis could potentially yield dual benefits by suppressing genes and enhancing the immunotherapeutic response in STAD, it's important to note that further experimental validation is required to delve into the molecular mechanisms linked to ALKBH1 in STAD.